Drugs / Nasal Glucagon
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02806973 | Jan → Apr 2015 | type 1 diabetes mellitus, type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02806960 | Jun 2014 | type 1 diabetes mellitus, type 2 diabetes mellitus | Eli Lilly and Company | Terminated | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2019-07-24 | Eli Lilly and Company | Regulatory BAQSIMI™ (glucagon) Nasal Powder 3 mg, the First and Only Nasally Administered Glucagon to Treat Severe Hypoglycemia in Adults and Children with Diabetes Ages Four Years and Older, Approved by FDA lilly.com ↗
The U.S. Food and Drug Administration (FDA) has approved BAQSIMI™ (glucagon) nasal powder 3 mg for the treatment of severe hypoglycemia in people with diabetes ages four years and above, Eli Lilly and Company (NYSE: LLY) announced today. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2019-07-24 | Eli Lilly and Company | BAQSIMI™ (glucagon) Nasal Powder 3 mg, the First and Only Nasally Administered Glucagon to Treat Severe Hypoglycemia in Adults and Children with Diabetes Ages Four Years and Older, Approved by FDA lilly.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nasal Glucagon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02806960 ↗ |
| Route | Intranasal | “Administered intranasally.” NCT02806960 ↗ |